MIRA

SEC filing MIRA Reports $1.2B Revenue, $0.45 EPS, +32% YoY Growth

6d ago

News EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million

14d ago

SEC filing MIRA Reports Positive Phase 1 Results for Ketamir‑2 in 57 Volunteers, No Serious AEs, Supports Once‑Daily Dosing

20d ago

SEC filing MIRA Reports SKNY-1 Achieves ~30% Weight Loss, Normalizes Cholesterol & HDL in 6‑Day Zebrafish Study

20d ago

SEC filing MIRA Reports Mira-55 Shows No THC/Cannabinoid Side Effects, Advances IND for Inflammatory Pain

71d ago

News MIRATECH Expands U.S. Catalyst Capacity with Acquisition of Advanced Catalyst Systems (ACS)

140d ago

Scanner Unusual volume (z=4.0)

160d ago

Scanner Unusual volume (z=4.2)

162d ago

Scanner Unusual volume (z=4.2)

163d ago

Scanner Unusual volume (z=4.2)

164d ago

Scanner Unusual volume (z=3.7)

165d ago